NASDAQ:BVS - Nasdaq - US09075A1088 - Common Stock - Currency: USD
7.26
-0.05 (-0.68%)
The current stock price of BVS is 7.26 USD. In the past month the price decreased by -23.66%. In the past year, price increased by 82.87%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 31.53 | 48.06B | ||
COO | COOPER COS INC/THE | 21.52 | 16.23B | ||
ALGN | ALIGN TECHNOLOGY INC | 18.94 | 12.94B | ||
SOLV | SOLVENTUM CORP | 9.81 | 11.35B | ||
LNTH | LANTHEUS HOLDINGS INC | 15.62 | 7.25B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 26.11 | 5.51B | ||
BLCO | BAUSCH + LOMB CORP | 24.15 | 4.10B | ||
ICUI | ICU MEDICAL INC | 22.02 | 3.37B | ||
HAE | HAEMONETICS CORP/MASS | 14.89 | 3.16B | ||
XRAY | DENTSPLY SIRONA INC | 8.34 | 2.78B | ||
UFPT | UFP TECHNOLOGIES INC | 27.94 | 1.63B | ||
NEOG | NEOGEN CORP | 13.55 | 1.12B |
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 930 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
BIOVENTUS INC - A
4721 Emperor Boulevard, Suite 100
Durham NORTH CAROLINA 27703 US
CEO: Kenneth M. Reali
Employees: 1030
Company Website: https://www.bioventus.com/
Investor Relations: https://ir.bioventus.com/stock-information/stock-quote-chart
Phone: 19194746700
The current stock price of BVS is 7.26 USD. The price decreased by -0.68% in the last trading session.
The exchange symbol of BIOVENTUS INC - A is BVS and it is listed on the Nasdaq exchange.
BVS stock is listed on the Nasdaq exchange.
7 analysts have analysed BVS and the average price target is 15.3 USD. This implies a price increase of 110.74% is expected in the next year compared to the current price of 7.26. Check the BIOVENTUS INC - A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOVENTUS INC - A (BVS) has a market capitalization of 594.88M USD. This makes BVS a Small Cap stock.
BIOVENTUS INC - A (BVS) currently has 1030 employees.
BIOVENTUS INC - A (BVS) has a support level at 5.91 and a resistance level at 7.74. Check the full technical report for a detailed analysis of BVS support and resistance levels.
The Revenue of BIOVENTUS INC - A (BVS) is expected to decline by -0.01% in the next year. Check the estimates tab for more information on the BVS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BVS does not pay a dividend.
BIOVENTUS INC - A (BVS) will report earnings on 2025-05-13, before the market open.
The PE ratio for BIOVENTUS INC - A (BVS) is 15.45. This is based on the reported non-GAAP earnings per share of 0.47 and the current share price of 7.26 USD. Check the full fundamental report for a full analysis of the valuation metrics for BVS.
The outstanding short interest for BIOVENTUS INC - A (BVS) is 1.34% of its float. Check the ownership tab for more information on the BVS short interest.
ChartMill assigns a technical rating of 4 / 10 to BVS. When comparing the yearly performance of all stocks, BVS is one of the better performing stocks in the market, outperforming 93.16% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to BVS. There are concerns on the financial health of BVS while its profitability can be described as average.
Over the last trailing twelve months BVS reported a non-GAAP Earnings per Share(EPS) of 0.47. The EPS increased by 79.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -4.61% | ||
ROE | -22.67% | ||
Debt/Equity | 2.15 |
ChartMill assigns a Buy % Consensus number of 77% to BVS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 41.11% and a revenue growth -0.01% for BVS